Cost-effectiveness of ribociclib plus letrozole palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
Background: The global burden of breast cancer (BC) is high, especially in advanced stages. CDK 4/6 inhibitors represent a paradigm shift in the treatment of advanced BC HR+/HER2−, given the clinically and statistically significant gain in overall survival associated with this new class of medicatio...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publishing
2021-04-01
|
| Serier: | Therapeutic Advances in Medical Oncology |
| Online adgang: | https://doi.org/10.1177/17588359211000593 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|